The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
CACA 2025 | AI-guided surgery and MRD integration in modern lung cancer care
Kezhong Chen, MD, Peking University People’s Hospital, Beijing, China, provides an overview of novel operative strategies for lung cancer in China. Minimal residual disease (MRD) can reflect real-world tumor burden in patients and can be integrated in staging systems. Identifying segmental pulmonary blood vessels and bronchi using artificial intelligence (AI) have additionally enabled more precise anatomical resection in surgery. This interview took place at the 2025 Chinese Anti-Cancer Association (CACA) Science & Technology Award Talks in Kunming, China.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
